source
- FDA releases draft guidance on container closure and device components for biosimilar combination productsThe FDA issued draft guidance aimed at helping sponsors develop container closure systems and device constituents for biosimilar and interchangeable biosimilar combination products. The guidance f…
- Bristol Myers pushes Cobenfy Alzheimer’s psychosis readout to early 2027 after enrollment delaysBristol Myers Squibb said the Phase 3 readout for its Cobenfy Alzheimer’s psychosis program will be postponed to early 2027. The company had previously expected data from the three Adept trials to…